TP53 and myelodysplastic syndrome: The incidence of TP53 mutations in lower-risk MDS patients has been evaluated in several studies: 2% in lower-risk MDS patients, as described by Bejar [10], 3% in lower-risk MDS patients and 19% in MDS patients with isolated del(5q), as reported by Kulasekararaj [11], and 18% in low-risk MDS patients with del(5q) in a study by Jädersten et al. [12].